
IP Osgoode is an independent voice that explores legal governance issues at the intersection of intellectual property (IP) and technology. The program’s researchers, collaborators, and students actively engage in some of the most important and cutting-edge IP law and technology related research and policy discussions of today.
Commentary and analysis on the latest developments in intellectual property, technology and privacy, featuring curated contributions from students, scholars, and experts within the Osgoode community.
2016 was a winning year for Western trademarks in China. It produced an unprecedented number of decisions – two, to be exact – in which China won praise for protecting foreign trademarks, affirming intellectual property rights, and developing a friendlier environment for international businesses. The only loser was trademark law itself, as the two decisions […]
Like it or not, some people spend a lot of money on art. When they do, art buyers are likely unhappy when they get something other than they bargained for. Modern forgeries are a thorn in the side of fine art buyers, sellers, and scholars.
As part of the IP Osgoode Speaks Series, Dr. Siva Thambisetty, an associate professor of law at the London School of Economics, visited Osgoode Hall Law School to speak on the subject of patent dialect. The main focus of her talk, entitled, "Is Patent Law Evasive or Merely Elusive?", was to highlight the issue of […]
The Intellectual Property Institute of Canada (IPIC) and IP Osgoode are delighted to announce our 2017 Canadian writing challenge in intellectual property law.
As ratification stutters for the Comprehensive Economic and Trade Agreement (CETA), the much-maligned free-trade deal between Canada and the European Union, debate continues as to whether the Canadian intellectual property (IP) regime will provide adequate protection for innovative biologic medicines in relation to subsequent-entry biologics (SEBs). Biologic medicines are complex molecules derived from living organisms […]
Yes, it is apparently possible – Elsevier just did it. Elsevier is one of the largest science and medical publishers in the world. Prestigious journals, such as Cell and The Lancet, are amongst its products. Over the years, it has been the subject of a number of criticisms, including its pricing regime (see here, here […]
Editor in Chief: Prof. Carys Craig (ccraig@osgoode.yorku.ca)
Submission inquiries: iposgoode@osgoode.yorku.ca